Portal vein thrombosis after splenectomy

Am J Surg. 2002 Dec;184(6):631-5; discussion 635-6. doi: 10.1016/s0002-9610(02)01095-4.

Abstract

Background: Portal vein thrombosis (PVT) has been described after splenectomy, but the factors associated with its development and the clinical outcomes are poorly characterized.

Methods: Case logs of four surgeons from 1996 to 2001 were retrospectively reviewed to identify cases of postsplenectomy PVT.

Results: Eight cases of PVT (8%) among 101 splenectomies were identified. Indications for splenectomy in patients with PVT were myeloproliferative disease (n = 4), hemolytic anemia (n = 3), and myelodysplastic disorder (n = 1). All patients had splenomegaly (mean 1698 g, range 360 to 3150 g). Among 10 patients with myeloproliferative disease (MP), 4 patients (40%) developed PVT, compared with 4 of 12 patients (25%) with hemolytic anemia. Three of 4 patients (75%) with MP disease and spleen weight greater than 3,000 g developed PVT. Five patients developed PVT despite receiving prophylactic subcutaneous heparin postoperatively. Presenting symptoms included anorexia in 7 (88%), abdominal pain in 6 (75%), and both elevated leukocyte and platelet counts in 8 patients (100%). All diagnoses were made by contrast-enhanced computed tomography scan, and anticoagulation was initiated immediately. One patient died of intraabdominal sepsis; the others are alive with no clinical sequelae at 38 months of follow-up.

Conclusions: PVT is a relatively common complication of splenectomy in patients with splenomegaly. A high index of suspicion, early diagnosis by contrast-enhanced computed tomography, and prompt anticoagulation are key to a successful outcome.

MeSH terms

  • Adult
  • Aged
  • Anticoagulants / therapeutic use
  • Female
  • Heparin / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Portal Vein*
  • Splenectomy / adverse effects*
  • Tomography, X-Ray Computed
  • Treatment Outcome
  • Venous Thrombosis / diagnosis*
  • Venous Thrombosis / drug therapy
  • Venous Thrombosis / etiology*
  • Warfarin / therapeutic use

Substances

  • Anticoagulants
  • Warfarin
  • Heparin